Hepatic Decompensation Likely Attributable to Simeprevir in Patients with Advanced Cirrhosis

BACKGROUND: Hyperbilirubinemia is a common side effect of protease inhibitors used to treat chronic hepatitis C (HCV), and most patients do not experience without clinically overt hepatotoxicity. The safety of second-wave protease inhibitors, including simeprevir, has not been well studied in patien...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Dig Dis Sci
Asıl Yazarlar: Stine, Jonathan G., Intagliata, Nicolas, Shah, Neeral L., Argo, Curtis K., Caldwell, Stephen H., Lewis, James H., Northup, Patrick G.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2014
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6600814/
https://ncbi.nlm.nih.gov/pubmed/25373453
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10620-014-3422-x
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller